Weekly topotecan in the management of ovarian cancer

Gynecologic Oncology

Volumn 90, Issue 3 SUPPL., 2003, Pages

  Morris, Robert T ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Myelosuppression; Relapsed ovarian cancer; Topotecan; Weekly dosing

Indexed keywords

CREATININE; PLATINUM; TOPOTECAN;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHRONOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE CLEARANCE; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG INFUSION; DRUG SENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; MAXIMUM TOLERATED DOSE; NEUTROPENIA; OVARY CANCER; PATIENT CARE; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0042733262     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00470-0     Document Type: Conference Paper

References (19)

1. Hensley M.L. Epithelial ovarian cancer. Curr Treat Options Oncol. 3:2002;131-141.
2. Ozols R.F. Update on the management of ovarian cancer. Cancer J. 8: (Suppl 1):2002;S22-30.
3. Latorre A., De Lena M., Catino A., Crucitta E., Sambiasi D., Guida M., et al. Epithelial ovarian cancer second and third line chemotherapy (review) . Int J Oncol. 21:2002;179-186.
4. Harries M., Gore M. Part II chemotherapy for epithelial ovarian cancer - treatment of recurrent disease . Lancet Oncol. 3:2002;537-545.
5. Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol 2003;90(3):S39-43.
6. Gadducci A., Conte P., Cianci C., Negri S., Genazzani A.R. Treatment options in patients with recurrent ovarian cancer. Anticancer Res. 21:2001;3557-3564.
7. Armstrong D., O'Reilly S. Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist. 3:1998;4-10.
8. Creemers G.J., Bolis G., Gore M., Scarfone G., Lacave A.J., Guastallo J.P., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer results of a large European Phase II study . J Clin Oncol. 14:1996;3056-3061.
9. ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Classic Papers Curr Comments. 7:2002;133-143.
10. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., Dunton C.J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma a Gynecologic Oncology Group study . J Clin Oncol. 18:2000;1062-1067.
11. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan . J Clin Oncol. 19:2001;3312-3322.
12. Bence A.K., Mattingly C.A., Desimone P.A., Doukas M.A., Adams V.R. Evaluation of topotecan cytotoxicity and topoisomerase I levels in non-small cell lung cancer cells. Proc Am Assoc Cancer Res. 43:2002;247. (poster 1227).
13. Haas N.B., LaCreta F.P., Walczak J., Hudes G.R., Brennan J.M., Ozols R.F., et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res. 54:1994;1220-1226.
14. Hoskins P., Eisenhauer E., Beare S., Roy M., Drouin P., Stuart G., et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer a National Cancer Institute of Canada Clinical Trials Group Study . J Clin Oncol. 16:1998;2233-2237.
15. Tan B.R., Picus J., Fracasso P.M., Clark R. Weekly bolus topotecan (T) update on a phase I dose escalation trial . Proc Am Soc Clin Oncol. 21:2002;A2149.
16. Homesley H.D., Hall D.J., Martin D.A., Lewandowski G.S., Vaccarello L., Nahhas W.A., et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol. 83:2001;394-399.
17. Morris R.T., Munkarah A., Field J., Baker V.V., Drake R., Malone J. Phase II trial of weekly topotecan in patients with potentially platinum sensitive relapsed ovarian and peritoneal cancer. Proc Am Soc Clin Oncol. 21:2002;A2512.
18. Morris R., Alvarez R.D., Andrews S., Malone J., Bryant C., Munkarah A. Topotecan weekly bolus chemotherapy for potentially chemosensitive relapsed ovarian and peritoneal cancer - an update. Proc Am Soc Clin Oncol. 22:2003;A1846.
19. Treat J. Weekly topotecan in lung cancer. Lung Cancer 2003;41(4):527-31.